Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKesson
Mallinckrodt
Baxter
Merck

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BREXANOLONE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for brexanolone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02603926 ↗ Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone Completed Randi J. Hagerman, MD Phase 2 2015-10-01 The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
NCT02603926 ↗ Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone Completed University of California, Davis Phase 2 2015-10-01 The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
NCT03665038 ↗ A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) Completed Sage Therapeutics Phase 3 2018-05-17 This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression.
NCT04273191 ↗ A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone) Withdrawn Sage Therapeutics Phase 4 2020-02-01 In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a physician as standard of care for postpartum depression (PPD) and who are planning to receive the infusion per United States Prescribing Information (USPI) at a Risk Evaluation and Mitigation Strategy (REMS)-certified healthcare center are being asked to participate to collect data on multimodal neuroimaging parameters in order to evaluate the relationship between changes in depressive symptoms and changes in neuroimaging parameters.
NCT04537806 ↗ A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19 Terminated Sage Therapeutics Phase 3 2020-12-18 The purpose of this study is to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
NCT05059600 ↗ A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting Not yet recruiting Sage Therapeutics Phase 4 2021-11-01 The primary purpose of this study is to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for brexanolone

Condition Name

Condition Name for brexanolone
Intervention Trials
Postpartum Depression 2
Acute Respiratory Distress Syndrome 1
COVID-19 1
Fragile X-associated Tremor/Ataxia Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for brexanolone
Intervention Trials
Depression, Postpartum 3
Depression 2
Syndrome 2
Depressive Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for brexanolone

Trials by Country

Trials by Country for brexanolone
Location Trials
United States 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for brexanolone
Location Trials
California 3
Georgia 2
North Carolina 2
Ohio 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for brexanolone

Clinical Trial Phase

Clinical Trial Phase for brexanolone
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for brexanolone
Clinical Trial Phase Trials
Completed 2
Terminated 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for brexanolone

Sponsor Name

Sponsor Name for brexanolone
Sponsor Trials
Sage Therapeutics 4
Randi J. Hagerman, MD 1
University of California, Davis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for brexanolone
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Colorcon
Dow
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.